Novartis announces trial setback on del-desiran drug

Swiss drugmaker Novartis on Tuesday said a late-stage study assessing drug ​del-desiran's impact on myotonic dystrophy, a ‌form of muscle wasting, had not met its target on a key metric, but reaffirme...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。